Michael J. Pellini, M.D.
Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology and healthcare. Prior to joining Section 32 in 2017, he served as CEO and Chairman of Foundation Medicine, a company that transformed the way pharmaceutical companies and physicians evaluate the genomic changes underlying a patient’s cancer. He transitioned to Foundation Medicine Chairman through the close of Roche’s acquisition of the company in August of 2018. Previously, he was President and Chief Operating Officer of Clarient, a national leader in molecular pathology. Clarient was acquired by GE Healthcare in 2010.